Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Open access
Kahl, Christoph, Storer, Barry E., Sandmaier, Brenda M., Mielcarek, Marco, Maris, Michael B., Blume, Karl G., Niederwieser, Dietger, Chauncey, Thomas R., Forman, Stephen J., Agura, Edward, Leis, Jose F., Bruno, Benedetto, Langston, Amelia, Pulsipher, Michael A., McSweeney, Peter A., Wade, James C., Epner, Elliot, Bo Petersen, Finn, Bethge, Wolfgang A., Maloney, David G., Storb, Rainer · 2007 · Blood

Abstract

Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for eradication of cancer. Here, we estimated relapse risks according to disease characteristics. Between 1997 and 2006, 834 consecutive patients (median age, 55 years; range, 5-74 years) received related (n = 498) or unrelated (n = 336) HCT after 2 Gy total body irradiation alone (n = 171) or combined with fludarabine (90 mg/m2; n = 663). Relapse rates per patient year (PY) at risk, corrected for follow-up and competing nonrelapse mortality, were calculated for 29 different diseases and stages. The overall relapse rate per PY was 0.36. Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) in remission (CR), low-grade or mantle cell non-Hodgkin lymphoma (NHL) (CR + partial remission [PR]), and high-grade NHL-CR had the lowest rates (0.00-0.24; low risk). In contrast, patients with advanced myeloid and lymphoid malignancies had rates of more than 0.52 (high risk). Patients with lymphoproliferative diseases not in CR (except Hodgkin lymphoma and high-grade NHL) and myeloid malignancies in CR had rates of 0.26-0.37 (standard risk). In conclusion, patients with low-grade lymphoproliferative disorders experienced the lowest relapse rates, whereas patients with advanced myeloid and lymphoid malignancies had high relapse rates after nonmyeloablative HCT. The latter might benefit from cytoreductive treatment before HCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-03-078592

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 163

Metadata

Authors
Kahl, C., Storer, B. E., Sandmaier, B. M., Mielcarek, M., Maris, M. B., Blume, K. G., Niederwieser, D., Chauncey, T. R., Forman, S. J., Agura, E., Leis, J. F., Bruno, B., Langston, A., Pulsipher, M. A., McSweeney, P. A., Wade, J. C., Epner, E., Bo Petersen, F., Bethge, W. A., Maloney, D. G., & Storb, R.
Venue
Blood
Published
2007-10-01
Volume
110
Issue
7
Pages
2744-2748
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2017978806
Cited by
163
References
1
FWCI
11.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. https://app.cochat.ai/papers/10.1182/blood-2007-03-078592
The paper
Kahl, C., Storer, B. E., Sandmaier, B. M., Mielcarek, M., Maris, M. B., Blume, K. G., Niederwieser, D., Chauncey, T. R., Forman, S. J., Agura, E., Leis, J. F., Bruno, B., Langston, A., Pulsipher, M. A., McSweeney, P. A., Wade, J. C., Epner, E., Bo Petersen, F., Bethge, W. A., . . . Storb, R. (2007). Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. https://doi.org/10.1182/blood-2007-03-078592

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.